TXG vs. BBP

In the year-to-date period, TXG achieves a -39.90% return, which is significantly lower than BBP's -8.34% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and Virtus LifeSci Biotech Products ETF (BBP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current TXG Sharpe Ratio is -0.89, which is lower than the BBP Sharpe Ratio of -0.01. The chart below compares the historical Sharpe Ratios of TXG and BBP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither TXG nor BBP has paid dividends to shareholders.

The maximum TXG drawdown since its inception was -96.47%, which is greater than BBP's maximum drawdown of -44.32%. Use the drawdown chart below to compare losses from any high point for TXG and BBP. For additional features, visit the drawdowns tool.

10x Genomics, Inc. (TXG) has a higher volatility of 27.07% compared to Virtus LifeSci Biotech Products ETF (BBP) at 11.58%. This indicates that TXG's price experiences larger fluctuations and is considered to be riskier than BBP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.